Permeation-enhanced MOF (Metal Organic Framework) drug-loaded nano preparation as well as preparation and application thereof
By responsively releasing drugs at the tumor site using copper-doped zeolite imidazole skeleton carrier, the problems of premature drug leakage and insufficient penetration depth in the prior art were solved, effective drug delivery and release in the tumor were achieved, and the chemotherapy effect was significantly improved .
Patent Information
- Application Number
- CN202411056718.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-02
- Publication Date
- 2024-11-29
AI Technical Summary
Premature drug leakage and insufficient penetration depth in solid tumors in existing nanodrug delivery systems are problems, especially in the tumor microenvironment, which is difficult to achieve effective drug delivery and release.
The copper-doped zeolite imidazole skeleton (Cu-ZIF-8) is used as a carrier to load gas donor drugs and chemotherapy drugs, and modify targeted substances on its surface to form an intelligent integrated nanocarrier that can responsively release drugs at tumor sites. , improve the penetration depth and accumulation of drugs.
Effective drug accumulation and deep penetration in the tumor site are achieved, the problems of poor gas molecules and short half-life in the blood are avoided, the therapeutic effect of chemotherapy drugs is significantly improved, and the drug delivery and release efficiency in the tumor is enhanced.
Smart Images

Figure CN119033955A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of nano drug preparations, and in particular to a permeation-enhanced MOF drug-loaded nano preparation, and its preparation and application. Background Art
[0002] Poor drug permeability in solid tumors is considered to be the main factor limiting the clinical benefits of nanomedicines. Compared with normal blood vessels, tumor blood vessels have an incomplete vascular network structure, high interstitial fluid pressure, and relatively low intratumoral blood perfusion. The distribution of drugs is usually limited to the perivascular area, which seriously hinders intratumoral drug delivery. In recent years, researchers have explored many strategies to enhance the penetration and accumulation of drugs in tumor tissues: (1) modifying nanoparticles based on their physical or chemical properties, such as pegylation of their surface to increase retention in the systemic circulation, or modifying them with specific targeting ligands (folate, hyaluronic acid, peptides, etc.) to promote cellular internalization; (2) killing cancer cells to reduce their barrier function, such as using X-ray therapy to give an appropriate amount of radiation to preferentially kill cancer cells near blood vessels, while inducing cancer cell damage without damaging the vascular system in tumor tissue, thereby temporarily increasing vascular permeability and improving the delivery of nanodrug molecules; (3) targeting the tumor vasculature or matrix, such as using anti-angiogenic drugs such as bevacizumab to normalize blood vessels and thus improve the distribution of blood in the tumor center, or using vascular mediators (such as bradykinin, nitric oxide (NO) releasers, proteases, etc.) to promote tumor vascular specific expansion, increase tumor blood flow, enhance EPR-mediated drug delivery, and improve drug delivery.
[0003] NO is an endogenous gaseous transmitter with free radical properties. It can diffuse rapidly through the cell membrane and act on adjacent target cells to exert its effects. It is involved in many physiological and pathological activities in cancer treatment. Many studies have confirmed that NO can regulate related genes (such as ANGPTI, VEGF, S1PR1), causing vascular smooth muscle relaxation and increased blood flow, thereby improving the function of tumor blood vessels. However, due to the reaction of oxygen and other compounds (such as superoxide anions, hemoglobin, etc.) present in the body, NO is extremely unstable outside the cell and has an extremely short half-life, which greatly increases the difficulty of its delivery and release in vivo. S-nitrosothiols (RSNO) such as S-nitrosoglutathione (GSNO), S-nitrosoalbumin (AlbSNO) and S-nitrosocysteine (CysNO) present in human plasma and tissue fluid are widely used for NO delivery as endogenous NO donors. However, these molecules have poor stability and a short half-life in the blood, so it is still a challenge to achieve NO delivery and release in biological systems. To solve this problem, researchers have established a variety of methods to encapsulate NO donors into prefabricated carriers (such as polymers, liposomes, hydrogels, and metal-organic frameworks, etc.), and control the production of NO under internal (such as pH, redox conditions) or external (such as heat, light, ultrasound, etc.) stimuli, thereby constructing a stimulus-responsive targeted drug delivery system. Among these methods, the production of NO by ion catalysis is increasingly favored by researchers, such as the use of copper to catalyze the decomposition of RSNO. In this process, the transition state Cu 2+ Reduced to Cu by sulfate + , which then induces Cu + Reacts with RSNO to release NO and regenerate Cu 2+ .
[0004] The size of nanocarriers has a great influence on their aggregation and metabolism at the tumor site. It is generally believed that nanoparticles with a size greater than 10 nm can selectively pass through the intercellular spaces of tumor blood vessels. When the size is less than 10 nm, although they have good tumor penetration ability, they will be quickly cleared out of the body and cannot be effectively enriched at the tumor site. In recent years, the research on nanocarriers has mainly focused on designing high drug loading and high enrichment at the tumor site, but the effects produced by these alone are far from enough. Stimuli-responsive release of drugs at the tumor site and deep penetration at the tumor site are also required. Metal-organic frameworks (MOFs) are widely used as nano drug delivery carriers to encapsulate biomacromolecules (proteins, nucleic acids, enzymes, etc.) and small organic molecules due to their high specific surface area, adjustable pore size, and high porosity, providing them with protection to avoid premature leakage and degradation during blood circulation. Most MOFs remain stable under physiological conditions and are degradable under acidic conditions, so they are an ideal pH-responsive drug carrier. Studies have shown that copper-containing MOFs can be used to enhance chemodynamic therapy (CDT). Under the weakly acidic conditions of the tumor microenvironment, they consume overexpressed glutathione (GSH) in the tumor and convert endogenous high-concentration H2O2 into highly toxic hydroxyl radicals (·OH), thereby disrupting the body's redox balance and exacerbating oxidative stress. GSH, as the main antioxidant in cells, maintains the redox balance in cells to a certain extent; reduced nicotinamide adenine dinucleotide phosphate (NADPH) is also a key antioxidant molecule in cells, participating in many biosynthesis and redox reactions in organisms. The circulation of the body's antioxidant system also depends on NADPH, which can provide electrons to reduce oxidized glutathione (GSSG) to GSH through glutathione reductase (GR), and convert itself into oxidized NADP. + , that is, the consumption of GSH will also cause the NADPH content to decrease, which also means that NADPH / NADP + The disruption of circulation will further disrupt the redox and energy metabolism homeostasis within the tumor. Summary of the invention
[0005] The present invention solves the problems of premature drug leakage and drug penetration depth in existing nano drug delivery systems. The present invention provides a method of using MOF (such as copper-doped zeolite imidazole framework Cu-ZIF-8) as a carrier to load gas donor drugs (NO donor drugs) and chemotherapeutic drugs, and then modifying the surface with a targeting substance to improve its stability to obtain an intelligent integrated nanocarrier. This nanocarrier can interact specifically with receptors overexpressed in tumor cells through active targeting, thereby effectively promoting the cancer cell internalization of the nanocarrier. This MOF drug-loaded nanoformulation can achieve responsive release of drugs at the tumor site without external stimulation, and also greatly improves the purpose of chemotherapeutic drugs being unable to achieve effective treatment due to their shallow penetration depth in solid tumors, bringing great application value to nanomedicines in clinical research.
[0006] According to a first aspect of the present invention, a permeability-enhanced MOF drug-loaded nanoformulation is provided, comprising a MOF carrier, a drug and a modifier; the drug is coated in the porous structure of the MOF carrier, and the drug is a small molecule chemotherapeutic drug and a gas donor drug; the modifier is modified on the surface of the MOF carrier, and the modifier is a hydrophilic ligand, a hydrophilic protein or a hydrophilic polypeptide that can specifically interact with a receptor overexpressed in tumor cells;
[0007] The gas donor drug is used to release gas in situ at the tumor site, thereby causing vascular smooth muscle relaxation and increased blood flow, so as to promote the accumulation and penetration of the small molecule chemotherapeutic drug at the tumor site.
[0008] Preferably, the small molecule chemotherapeutic drug is one or more of curcumin, catechin, gallic acid, paclitaxel, thymoquinone, tamoxifen, vinorelbine, gefitinib, afatinib, osimertinib, crizotinib, topotecan, irinotecan, docetaxel, isabitone, capecitabine, tamoxifen, trastuzumab, lapatinib, doxorubicin hydrochloride and doxorubicin; preferably curcumin.
[0009] Preferably, the gas donor drug is an NO donor drug, an H2S donor drug or a CO donor drug.
[0010] Preferably, the NO donor drug is a nitrate drug, sodium nitroprusside, L-arginine or a nitroso complex; the H2S donor drug is sodium hydrosulfide, sodium sulfide, anethole, aspirin, naproxen, ibuprofen or diclofenac; the CO donor drug is tricarbonyl chloride (glycine) ruthenium, dimanganese decacarbonyl, oxalic acid, borocarboxylate, silicon carboxylate or xanthene carboxylate;
[0011] Preferably, the nitrate drug is nitroglycerin, and the nitroso compound is S-nitrosoglutathione.
[0012] Preferably, the modification is carried out by covalent bonding or electrostatic adsorption;
[0013] Preferably, the hydrophilic ligand is hyaluronic acid, folic acid or ubiquitin ligase.
[0014] Preferably, the MOF carrier is a zeolite imidazole framework, a Lavoisier framework material or a porous coordination network.
[0015] According to another aspect of the present invention, a method for preparing any one of the permeation-enhanced MOF drug-loaded nanoformulations is provided, comprising the following steps:
[0016] (1) adding a small molecule chemotherapeutic drug and a gas donor drug to the MOF carrier and mixing them thoroughly so that the small molecule chemotherapeutic drug and the gas donor drug are encapsulated in the porous structure of the MOF carrier to obtain a solution of MOF drug-loaded nanoparticles;
[0017] (2) adding a modifier to the solution obtained in step (1), wherein the modifier is a hydrophilic ligand, hydrophilic protein or hydrophilic polypeptide that can specifically interact with receptors overexpressed in tumor cells, and the modifier is connected to the surface of the MOF carrier, washed and resuspended to obtain a modifier-modified MOF drug-loaded nanoformulation, i.e., the permeability-enhanced MOF drug-loaded nanoformulation.
[0018] According to another aspect of the present invention, there is provided a use of any one of the permeability-enhanced MOF drug-loaded nanoformulations in the preparation of tumor therapeutic drugs.
[0019] Preferably, the application is specifically as follows: under the conditions of the tumor microenvironment, the permeability-enhanced MOF drug-loaded nanoformulation is used to degrade and release small molecule chemotherapeutic drugs and gas donor drugs, and the gas donor drug is used to release gas in situ at the tumor site, thereby causing vascular smooth muscle relaxation and increased blood flow, so as to promote the accumulation and penetration of the small molecule chemotherapeutic drugs at the tumor site.
[0020] In general, the above technical solution conceived by the present invention has the following technical advantages compared with the prior art:
[0021] (1) The permeability-enhanced MOF drug-loaded nanoformulation prepared by the present invention can release drugs in response to degradation under low pH and high GSH content in the tumor microenvironment and regulate the energy metabolism of in situ tumors and enhance drug penetration through a cascade catalytic process. Tumor cells obtain energy to maintain their own growth by breaking chemical bonds in nutrients, and the MOF drug-loaded nanoformulation prepared by the present invention can consume NADPH through deep cryomicroscopy optical sectioning tomography system monitoring, so that the cell energy supply is slowed down, and tumor growth is inhibited. The present invention encapsulates the gas donor in MOF and specifically releases the gas in situ at the tumor site, thereby avoiding the problem of poor stability of gas molecules and short half-life in the blood. This causes vascular smooth muscle relaxation and increased blood flow to promote the accumulation and deep penetration of more small molecule chemotherapy drugs at the tumor site, so that the chemotherapy drugs penetrate deep into the solid tumor for treatment, solving the problem that the drug penetration depth in the existing nanoformulations is shallow in solid tumors and cannot achieve effective treatment.
[0022] (2) The MOF-loaded drug nanoformulation designed in the present invention has good biocompatibility and responsive degradation ability, and can not only release drugs in a controlled manner under the conditions of the tumor microenvironment, but also release Cu in an acid-responsive manner in the tumor microenvironment after disintegration without external stimulation (light, heat, ultrasound, etc.). 2+ , which can be reduced to Cu by GSH overexpressed in the tumor + In this process, the redox balance between GSH and GSSG is broken, causing the NADPH content to decrease, which in turn leads to the NADPH / NADP + The circulation is also disrupted, the redox and energy metabolism homeostasis in the tumor is further disrupted, and cell proliferation is inhibited. + It can not only react with H2O2 to produce highly toxic ·OH through a Fenton-like reaction, exerting its chemical kinetics, but also + It can also catalyze the in situ release of NO from NO donors, increase the permeability of tumor blood vessels, significantly promote the accumulation of nanocarriers at the tumor site and the deep penetration of chemotherapeutic drugs. The treatment strategy under multi-modal coordination can further improve the effect of tumor treatment.
[0023] (3) The permeability-enhanced MOF drug-loaded nanoformulation constructed by the present invention can be a diagnostic reagent that integrates chemodynamic therapy, gas therapy, and chemotherapy multimodality. Compared with traditional chemotherapy, the effectiveness of chemotherapy drugs is seriously reduced due to the rapid clearance and non-specific distribution of drugs, which inevitably causes systemic toxic side effects and also causes tumor cells to develop drug resistance. However, due to the limited depth of light penetration into biological tissues, photothermal therapy and photodynamic therapy are often ineffective in treating deep tumors, and will inevitably cause damage to surrounding normal tissues. In recent years, non-invasive therapies have developed rapidly. The MOF drug-loaded nanoformulation prepared by this invention can achieve responsive release of drugs at the tumor site without external stimulation, and also greatly improves the purpose of chemotherapy drugs being unable to achieve effective treatment due to shallow penetration depth, bringing great application value to clinical research.
[0024] (4) Preferably, the present invention releases gas responsively (sound, heat, pH, etc.) by encapsulating the gas donor drug in MOF. When the gas donor drug is NO, it can stimulate the increase of cyclic guanosine monophosphate levels in smooth muscle cells, thereby relaxing vascular smooth muscle and increasing blood flow. When the gas donor drug is H2S, H2S can promote drug penetration by reducing the interstitial fluid pressure in the tumor, improving vascular permeability, and promoting angiogenesis. When the gas donor is CO, it has the effect of dilating blood vessels and inhibiting the proliferation of vascular smooth muscle cells, similar to NO. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Figure 1These are transmission electron micrographs of MOF (A), MOF drug-loaded nanoparticles (B), and MOF drug-loaded nanoformulations (C) in Example 1 of the present invention.
[0026] Figure 2 Transmission electron microscopy images of the responsive degradation of the MOF drug-loaded nanoformulation in Example 2 of the present invention under different conditions and at different time points.
[0027] Figure 3 This is a graph showing the consumption of GSH by the MOF drug-loaded nanoformulation in Example 3 of the present invention at different time points and its quantitative results.
[0028] Figure 4 This is a graph showing the changes in NO produced by the MOF drug-loaded nanoformulation in Example 4 of the present invention at different concentrations.
[0029] Figure 5 This is a drug release curve of the MOF drug-loaded nanoformulation in Example 5 of the present invention under different pH conditions.
[0030] Figure 6 These are fluorescent phagocytosis microscopic images of the MOF drug-loaded nanoformulation in Example 6 of the present invention measured after incubation with 4T1 cells at different time points.
[0031] Figure 7 This is the cell survival rate measured after the MOF drug-loaded nanoformulation in Example 7 of the present invention was co-incubated with three types of cells.
[0032] Figure 8 The whole fluorescence imaging diagram of the MOF drug-loaded nanoformulation at different time points after being injected into mice in Example 8 of the present invention.
[0033] Fig. 9 These are deep cryo-microscopic optical section tomographic images of the MOF drug-loaded nanoformulation in Example 9 of the present invention at different time points after being injected into mice.
[0034] Fig.10 This is a curve chart showing the change in tumor volume over time of mice after the MOF drug-loaded nanoformulation in Example 10 of the present invention was injected into the body of mice and the treatment observation was completed.
[0035] Fig.11 This is a CD31 stained section of blood vessels at the tumor site after the MOF drug-loaded nanoformulation in Example 11 of the present invention was injected into mice.
[0036] Fig.12 This is a drug penetration slice of the tumor site after the MOF drug-loaded nanoformulation in Example 12 of the present invention was injected into the mouse. DETAILED DESCRIPTION
[0037] In order to make the purpose, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention. In addition, the technical features involved in the various embodiments of the present invention described below can be combined with each other as long as they do not conflict with each other.
[0038] The invention provides a permeability-enhanced MOF drug-loaded nano preparation, a preparation method thereof and an application thereof in anti-tumor aspects.
[0039] Furthermore, the MOF is a zeolite imidazolate framework (ZIF), a Lavoisier framework material (MIL), or a poly-void coordination network (PCN), preferably a MOF material with a zeolite structure synthesized by reacting Zn(II) or Co(II) with an imidazole ligand.
[0040] Furthermore, the MOF material is Cu-ZIF-8 synthesized by coordination of Zn(II), Cu(II) and 2-methylimidazole (MIL), and its particle size is about 60-80nm and the potential is 20-40mv; the particle size of the penetration-enhanced MOF drug-loaded nanoformulation is about 80-120nm and the potential is -20--40mv.
[0041] Furthermore, the tumor drug loaded in the MOF nanoformulation is selected from tumor therapeutic agents of small molecule chemotherapeutic drugs and gas donor drugs.
[0042] Furthermore, the targeting substance used to improve the stability of MOF is a hydrophilic polypeptide, a hydrophilic protein or a hydrophilic ligand; the modification method is covalent bonding or electrostatic adsorption. The targeting substance for modifying MOF is preferably a ligand hyaluronic acid that specifically interacts with receptors overexpressed in tumor cells.
[0043] Further, the small molecule chemotherapeutic drug is selected from one or more of curcumin, catechin, gallic acid, paclitaxel, thymoquinone, tamoxifen, vinorelbine, gefitinib, afatinib, osimertinib, crizotinib, topotecan, irinotecan, docetaxel, ixabepine, capecitabine, tamoxifen, trastuzumab, lapatinib, doxorubicin hydrochloride, etc. Curcumin is preferred.
[0044] Further, the gas donor drug is selected from drugs that can promote vascular smooth muscle relaxation, increase blood flow, and improve tumor vascular function. NO donor drugs include nitrate drugs such as nitroglycerin, sodium nitroprusside, L-arginine, and nitroso compounds; H2S donor drugs include sodium hydrosulfide, sodium sulfide, anisole, aspirin, naproxen, ibuprofen, and diclofenac derivatives; CO donor drugs include tricarbonyl chloride (glycine) ruthenium (II), dimanganese decacarbonyl, oxalic acid, boron carboxylates, silicon carboxylates, xanthene carboxylates, etc. The NO donor drug nitroso complex S-nitrosoglutathione is preferred.
[0045] The present invention also provides a method for preparing a permeation-enhanced MOF drug-loaded nanoformulation, comprising the following steps:
[0046] Synthesis of MOF drug-loaded nanoformulation: 10-30 mL of 0.05M-0.2M zinc nitrate hexahydrate and 5-20 mL of 0.05M-0.2M copper nitrate trihydrate are taken in a methanol solution and mixed thoroughly, then added to 100-300 mL of a dimethylimidazole solution containing 0.5-2.5 g, stirred at room temperature for 0.2-1 hour, centrifuged, washed with methanol, and resuspended to obtain a MOF solution; 1-5 mL of the MOF solution is added with 5-15 mg / mL PVP-modified S-nitrosoglutathione and curcumin, mixed evenly, stirred at room temperature for 2-8 hours, centrifuged, and washed with methanol to obtain MOF drug-loaded particles; and then 1-5 mg / mL of hyaluronic acid solution is added, stirred at room temperature for 1-6 hours, centrifuged, washed with ultrapure water, and resuspended in water to obtain a hyaluronic acid-modified MOF drug-loaded nanoformulation.
[0047] Furthermore, the preparation method comprises the following steps:
[0048] (1) Dissolve 0.05M-0.2M zinc nitrate hexahydrate in 10-30mL methanol solution and 0.05M-0.2M copper nitrate trihydrate in 5-20mL methanol solution respectively, add the solution to a solution containing 0.5-2.5g dimethylimidazole by ultrasonication, stir vigorously at room temperature for 0.2-1 hour, centrifuge and wash with methanol 2-4 times, the centrifugal speed is 8000-11000rpm, the centrifugal time is 5-20 minutes, collect the precipitate, resuspend it in methanol solution to obtain MOF solution, and store it in a refrigerator at 4°C for later use;
[0049] (2) Take 10-60 mg of S-nitrosoglutathione and add it to a methanol solution (2-4 mL) of polyvinyl pyrrolidone (PVP) to obtain PVP-modified S-nitrosoglutathione. Take another 4-40 mg of curcumin and dissolve it in 2-5 mL of methanol solution. Take 1-5 mL of the MOF solution prepared in step (1), add 5-15 mg / mL PVP-modified S-nitrosoglutathione and 2-8 mg / mL curcumin at concentrations respectively, mix well, slowly stir at room temperature for 2-8 hours, centrifuge and wash with methanol 2-4 times until the supernatant is colorless, the centrifugal speed is 8000-11000 rpm, the centrifugal time is 5-20 minutes, and collect the precipitate to obtain MOF drug-loaded nanoparticles.
[0050] (3) After dissolving 4-60 mg of hyaluronic acid in 4-12 mL of ultrapure water to obtain an aqueous solution of hyaluronic acid, the precipitate in step (2) is fully dissolved in the aqueous solution of hyaluronic acid and stirred at room temperature for 1-6 hours, centrifuged and washed with ultrapure water 2-4 times to remove free hyaluronic acid molecules, the centrifugal speed is 8000-11000 rpm, the centrifugal time is 5-20 minutes, the precipitate is collected and resuspended in water to obtain the MOF drug-loaded nanoformulation (GC@Cu-Z@HA), and stored in a refrigerator at 4°C for later use.
[0051] The present invention also provides the use of the permeability-enhanced MOF drug-loaded nano-preparation in the preparation of tumor treatment drugs, preferably in the preparation of drugs for treating breast cancer malignant tumors.
[0052] The MOF drug-loaded nanoformulation can responsively degrade and catalyze the cascade reaction to exert its drug efficacy without external stimulation (light, heat, ultrasound, etc.). The responsive degradation conditions are lower pH and higher GSH content in the tumor microenvironment, with a pH range of 5.0-6.8 and a GSH content of 0.5mM-2.5mM. The specific process is that when the hyaluronic acid in the MOF drug-loaded preparation specifically interacts with the CD44 receptor overexpressed in tumor cells, it releases Cu through acid degradation in the tumor microenvironment. 2+ , which is reduced to Cu by the overexpressed GSH in the tumor + ,Cu + It can not only catalyze the high content of H2O2 in the tumor to produce highly toxic hydroxyl free radicals through a Fenton-like reaction, thereby enhancing the effect of chemodynamic therapy, but also release NO in situ through ion-catalyzed S-nitrosoglutathione, causing vascular smooth muscle relaxation and increased blood flow, increasing the permeability of tumor blood vessels, and significantly promoting the accumulation of nanocarriers at the tumor site and the deep penetration of drugs.
[0053] Preferably, when used, the concentration of the drug-loaded nanoformulation is 10 μg / mL-1000 μg / mL.
[0054] When the MOF drug-loaded nanoformulation is coated with the drug curcumin, the permeability-enhanced MOF drug-loaded nanoformulation can also be used in the preparation of fluorescence imaging applications. Or the monitoring and tracking of energy metabolism status using a deep low-temperature microscopic optical sectioning tomography system (-100 to -200°C) (Cryo-imaging) has practical guiding significance for understanding body functions and the diagnosis and treatment of diseases.
[0055] The following are specific embodiments
[0056] Example 1: Preparation and characterization of MOF and MOF-loaded drug nanoformulations
[0057] Dissolve 0.05M-0.2M zinc nitrate hexahydrate in 10-30mL methanol solution and 0.05M-0.2M copper nitrate trihydrate in 5-20mL methanol solution respectively, add to a solution containing 0.5-2.5g dimethylimidazole after ultrasonication to obtain a uniform solution, stir vigorously at room temperature for 0.2-1 hour, centrifuge and wash with methanol 2-4 times, the centrifugal speed is 8000-11000rpm, the centrifugal time is 5-20 minutes, collect the precipitate and resuspend it in methanol solution to obtain MOF solution, and store it in a refrigerator at 4°C for later use;
[0058] 10-60 mg of S-nitrosoglutathione is added to a methanol solution (2-4 mL) of polyvinyl pyrrolidone (PVP) to obtain PVP-modified S-nitrosoglutathione (GSNO). 4-40 mg of curcumin (Cur) is dissolved in 2-5 mL of methanol solution. 1-5 mL of the MOF solution prepared in step (1) is taken, and 5-15 mg / mL PVP-modified GSNO and 2-8 mg / mL Cur are added and mixed thoroughly. The mixture is slowly stirred at room temperature for 2-8 hours and centrifuged and washed 2-4 times with methanol until the supernatant is colorless. The centrifugal speed is 8000-11000 rpm, and the centrifugal time is 5-20 minutes. The precipitate is collected to obtain a MOF drug-loaded nanoformulation.
[0059] After dissolving 4-60 mg of hyaluronic acid in 4-12 mL of ultrapure water to obtain an aqueous solution of hyaluronic acid, the precipitate in step (2) is fully dissolved in the aqueous solution of hyaluronic acid and stirred at room temperature for 1-6 hours, centrifuged and washed with ultrapure water 2-4 times to remove free hyaluronic acid molecules, the centrifugal speed is 8000-11000 rpm, the centrifugal time is 5-20 minutes, the precipitate is collected and resuspended in a methanol solution to obtain a MOF drug-loaded nanoformulation, and stored in a refrigerator at 4°C for later use.
[0060] Here, the nanoformulation without drug encapsulation is recorded as Cu-ZIF-8@HA, the MOF drug-loaded nanoformulation encapsulating only GSNO is recorded as G@Cu-Z@HA, the MOF drug-loaded nanoformulation encapsulating only Cur is recorded as C@Cu-Z@HA, and the MOF drug-loaded nanoformulation encapsulating both GSNO and Cur is recorded as GC@Cu-Z@HA.
[0061] Take 20 μL of the prepared MOF and MOF drug-loaded nanoformulation solution and drop it on the copper mesh. Use filter paper to absorb excess water and dry it naturally. Then use transmission electron microscopy to observe its morphology. Figure 1 As shown. Figure 1 It can be seen that the transmission electron microscopy TEM results show that MOF presents a geometric dodecahedral nanostructure ( Figure 1 A in the figure is uniformly distributed and has a size of about 85 nm. When GSNO and Cur are loaded on the MOF surface, GC@Cu-Z nanoparticles are spherical ( Figure 1 B), the distribution is relatively uniform, and the size is about 90nm. When it is modified with hyaluronic acid HA, the results show that the surface of the MOF drug-loaded nanoformulation GC@Cu-Z@HA is relatively rough, and the size is slightly increased to about 100nm ( Figure 1 C), good dispersibility.
[0062] Example 2: pH and GSH dual-responsive degradation of MOF drug-loaded nanoformulations
[0063] 1-10 mL of the MOF drug-loaded nanoformulation solution (1-4 mg / mL) prepared in Example 1 was dispersed in different pH solutions containing / not containing GSH (0.5-2.5 mM) under dark conditions, and divided into four groups: pH 7.4, pH 6.5, pH 7.4+GSH, and pH 6.5+GSH. At different time points (1, 2, and 4 h), 20 μL was dropped on a copper grid, and the excess water was absorbed with filter paper, and the morphology was observed using a transmission electron microscope after natural drying. The results are shown in Figure 2. Figure 2 As shown. Figure 2 It can be seen that the TEM results show that the structure of the MOF drug-loaded nanoformulation stored in a neutral solution remains intact and evenly dispersed at different time points; however, under acidic conditions, it shows obvious degradation, and the degradation is time-dependent, the system dispersibility becomes worse, and the morphology of the nanoparticles becomes very irregular. After the acidic peptide GSH is added to the neutral solution, the MOF drug-loaded nanoformulation will also degrade, and the MOF drug-loaded nanoformulation will degrade faster in an acidic solution containing GSH than in a simple acidic solution.
[0064] Example 3: Detection of GSH consumption by MOF-loaded drug nanoformulations
[0065] 1-10 mL of the MOF drug-loaded nanoformulation solution (1-4 mg / mL) prepared in Example 1 and GSH (0.5-2.5 mM) were placed in a phosphate buffer solution at pH 6.5 and mixed with 5,5'-dithiobis(2-nitrobenzoic acid) (5-20 μg / mL). The absorption spectrum of the system was detected at a preset time point, and the GSH loss rate at different times was calculated by measuring the absorption value at 412 nm. Three parallels were set for each group. The results are shown in Figure 2. Figure 3 As shown. Figure 3 It can be seen that with the extension of reaction time, the absorption peak of the system gradually decreases ( Figure 3 A in the figure indicates that the GSH in the system is decreasing; quantitative analysis of the absorption at 412 nm shows that the loss of GSH after 12 h can reach 75.93% ( Figure 3 B), indicating that MOF-loaded drug nanoformulations can effectively consume GSH.
[0066] Example 4: Detection of NO production by MOF-loaded nanoformulation
[0067] 1-10 mL of the MOF drug-loaded nanoformulation solution (1-4 mg / mL) prepared in Example 1 and GSH (0.5-2.5 mM) were mixed in a phosphate buffer solution at pH 6.5. The solution was taken out at a preset time point, centrifuged at 11000 rpm for 15 min, and the supernatant was taken to measure the release of NO using a nitric oxide detection kit. Three parallels were set for each group. The results are shown in Figure 2. Figure 4 As shown. Figure 4 It can be seen that the results show that the release amount of NO is positively correlated with the concentration of MOF drug-loaded nanoformulations, and the release amount gradually increases with time.
[0068] Example 5: Drug release curves of MOF-loaded nanoformulations under different pH conditions
[0069] 2-10 mL of the MOF drug-loaded nanoformulation solution (1-4 mg / mL) prepared in Example 1 was dispersed in phosphate buffers of pH 7.4 and pH 6.5, respectively, and shaken in an air bath shaker at 37°C for 12 h. A certain amount of the solution was centrifuged at 11000 rpm for 15 min at 1, 2, 3, 4, 5, 6, 8, 10, and 12 h. The specific absorption value of the small molecule chemotherapeutic agent was determined by ultraviolet absorption spectroscopy, and then resuspended and returned to the original solution. Three parallels were set for each group. The results are shown in Table 1. Figure 5 As shown. Figure 5 It can be seen that the Cur release rate at pH 6.5 is significantly higher than that at pH 7.4.
[0070] Example 6: Phagocytosis of MOF-loaded nanoformulations and 4T1 cells at different time points after incubation
[0071] The phagocytosis was determined by observing the distribution of the fluorescence of the small molecule chemotherapeutic agent itself in the cell. 4T1 cells in the logarithmic growth phase were inoculated in a confocal microplate for overnight culture. After removing the culture medium, 1 mL of serum-free culture medium containing MOF drug-loaded nanoformulation (50 μg / mL) prepared in Example 1 was added and incubated for 1, 2, 4, and 6 hours, then washed three times with PBS, stained with DAPI for 10 minutes, and the distribution of Cur in the cell was observed under a confocal microscope after washing. The results are shown in Figure 2. Figure 6 As shown. Figure 6 It can be seen that as the incubation time increases, the green fluorescence in the cells continues to increase, which means that more and more MOF-loaded nanoformulations are internalized into the cells, and Cur green fluorescence appears in the cell nucleus. This shows that after the MOF-loaded nanoformulations enter the tumor cells, the nanocarrier structure undergoes acid degradation and releases Cur.
[0072] Example 7: Cell viability after co-incubation of MOF-loaded nanoformulations with three types of cells
[0073] Cytotoxicity test was determined by MTT method. Mouse embryonic fibroblast 3T3, mouse breast cancer 4T1, and human breast cancer MDA-MB-231 cells in logarithmic growth phase were inoculated in 96-well plates and cultured overnight, and then the culture medium was removed. Five parallel wells were set in each group, and 200 μL of serum-free culture medium containing different concentrations (6.25, 12.5, 25, 37.5, 50 μg / mL) of MOF drug-loaded nanoformulation prepared in Example 1 was added respectively. After 6 hours, the above culture medium was removed and washed three times with PBS. After each well was cultured with complete culture medium for 24 hours, 20 μL of thiazolyl blue (5 mg / mL) was added. After 4 hours, the culture medium was removed, and 150 μL of DMSO was added and placed on a shaker for slow shaking for 20 minutes. The absorption at 490 nm was measured by an enzyme marker to calculate the cell survival rate. The results are as follows: Figure 7 As shown. Figure 7 It can be seen that even at a concentration of 50 μg / mL, 3T3 cells still showed a cell survival rate of 89.09%, indicating that the MOF drug-loaded nanoformulation itself has low toxicity to normal cells and has good biocompatibility. The relatively high content of GSH and H2O2 in the tumor cell microenvironment provides good conditions for the tumor microenvironment, thus having a significant killing effect on the two cancer cells 4T1 and MDA-MB-231, showing a significant concentration dependence.
[0074] Example 8: Application of MOF drug-loaded nanoformulations in fluorescence imaging
[0075] The application of Cur in MOF-loaded nanoformulations in fluorescence imaging was evaluated by observing the fluorescence distribution of Cur in MOF-loaded nanoformulations. First, a tumor model was established. Six-week-old female Balb / C mice were inoculated with 4T1 cells (106 ) Construct an orthotopic breast cancer tumor model and wait until the tumor volume grows to 150mm 3 100 μL of the MOF drug-loaded nanoformulation (10 mg / mL) prepared in Example 1 was injected intratumorally into orthotopic tumor-bearing mice, and live fluorescence imaging of anesthetized mice was performed continuously at different time points (0, 0.1, 4, 8, 12, 24, 48, and 72 h) using a whole-body fluorescence imaging system. The results are shown in Figure 2. Figure 8 As shown. Figure 8 It can be seen that no fluorescence signal was detected at the tumor site before injection, but after intratumoral injection of the MOF-loaded nanoformulation, an obvious Cur fluorescence signal appeared at the tumor site. As time went on, the fluorescence signal gradually weakened until it disappeared. This may be because the Cur loaded in the MOF-loaded nanoformulation entered the tumor site with the injection, and the MOF-loaded nanoformulation gradually degraded in the tumor, and Cur also diffused to the surrounding area of the tumor.
[0076] Example 9: Monitoring energy metabolism of MOF-loaded nanoformulations by deep cryo-microscopy optical sectioning tomography
[0077] The energy metabolism changes in the tumor site were monitored by a deep cryo-microscopic optical sectioning tomography system. The in situ breast cancer tumor model constructed in Example 8 was taken and the tumor volume grew to 150 mm. 3 At the same time, 100 μL of the MOF drug-loaded nanoformulation (10 mg / mL) prepared in Example 1 was injected intratumorally into orthotopic tumor-bearing mice, and the tumors at different time points (0.1, 1, 2, 4, 6, and 12 h) were quickly placed in liquid nitrogen and subjected to deep cryogenic imaging. The results are shown in Fig. 9 As shown. Fig. 9 It can be seen that before the injection of MOF-loaded nanoformulations, NADPH in the tumor tissue area was mostly in a reduced state, with strong fluorescence and similar intensity values ( Fig. 9 A, B in the figure); 0.1h after the injection of MOF-loaded nanoformulation, the fluorescence signal of NADPH gradually weakened with the extension of time, while the distribution law of FAD fluorescence intensity was just the opposite, and the distribution law of redox ratio was consistent with the distribution law of NADPH fluorescence intensity; at 12h, the fluorescence signal of NADPH was the weakest, while the fluorescence signal of FAD was the strongest, that is, the NADPH / (NADPH+FAD) value was the smallest, indicating that the tumor tissue was in a strong oxidized state at this time.
[0078] Example 10: Evaluation of the therapeutic effect of MOF-loaded nanoformulations in in situ tumor-bearing mice
[0079] The therapeutic effect was comprehensively evaluated by observing the tumor volume and section staining of mice. First, a tumor model was established. Six-week-old female Balb / C mice were inoculated with 4T1 cells (10 6 ) Construct an orthotopic breast cancer tumor model and wait until the tumor volume grows to 100 mm 3 At about 1:10 pm, mice bearing 4T1 orthotopic tumors were randomly divided into a control group and a treatment group. On days 0, 3, and 6, 100 μL PBS and the MOF drug-loaded nanoformulation group (10 mg / mL) prepared in Example 1 were injected intratumorally for a total of three times. The changes in tumor volume of each group of mice were recorded every other day using a digital vernier caliper. The results are shown in Figure 2. Fig.10 As shown. Fig.10 It can be seen that the tumor volume of the mice in the control group increased rapidly over time. The growth rate of the tumor volume of the mice in the Cu-ZIF-8@HA group, a MOF drug-loaded nanoformulation without drug encapsulation, was significantly inhibited due to the chemokinetic effect at the tumor site. The tumor volume of the tumor-bearing mice in the MOF-loaded single drug group G@Cu-Z@HA and C@Cu-Z@HA was further inhibited. These are the effects of chemokinetic combined with NO treatment and chemokinetic combined with chemotherapy. The MOF drug-loaded nanoformulation group GC@Cu-Z@HA showed the best inhibitory effect.
[0080] Example 11: Effects of MOF-loaded Nanoformulations on Blood Vessels of Tumor-Bearing Mice
[0081] The effect on blood vessels was evaluated by CD31 staining of tumor sections of tumor-bearing mice. 3 At about 1:100 μL of PBS and the MOF drug-loaded nanoformulation (10 mg / mL) prepared in Example 1 were injected intratumorally. After one day of observation, the mice were killed and the tumors were removed and washed several times and immersed in 4% paraformaldehyde. After fixation for 48 hours, CD31 sections were embedded and observed and photographed under a confocal microscope. The results are shown in Fig.11 As shown. Fig.11 It can be seen that a slight red fluorescence signal was observed in the tumor tissue of the control group and the MOF drug-loaded nanoformulation Cu-ZIF-8@HA group without drug encapsulation, while the MOF drug-loaded nanoformulation G@Cu-Z@HA treatment group encapsulating gas donor drugs showed a stronger red fluorescence signal. It was also observed that the proportion of vascular dilation in this group increased significantly (white arrows indicate dilated tumor blood vessels), and the vascular endothelial tissue was also relatively intact.
[0082] Example 12: Drug penetration of MOF-loaded nanoformulations in mouse tumor sites
[0083] The fluorescence distribution of the small molecule chemotherapeutic agent contained in the MOF drug-loaded nanoformulation was observed by peritumoral injection. The in situ breast cancer tumor model constructed in Example 8 was taken and the tumor volume grew to 150 mm. 3 At about 1:10 pm, 100 μL PBS and the MOF drug-loaded nanoformulation group (10 mg / mL) prepared in Example 1 were injected intratumorally. After one day of observation, the mice were killed and the tumors were removed and immediately placed in liquid nitrogen, then embedded in OCT, and sliced on a cryostat and observed and photographed under a confocal microscope. Fig.12 As shown. Fig.12 It can be seen that in mice treated with free drug Cur, only a very small amount of fluorescence was detected in the entire tumor, and it was mainly distributed around the local area of the tumor ( Fig.12 ). In contrast, the tumors treated with the MOF-loaded nanoformulation C@Cu-Z@HA, which encapsulates chemotherapy drugs, showed strong fluorescence signals throughout the tumor tissue, but the fluorescence was mainly distributed around the tumor tissue. The fluorescence of the tumors treated with GC@Cu-Z@HA was stronger, and obvious fluorescence could be observed throughout the tumor tissue. The distribution range in the tumor was also wider, indicating that the drug penetration effect was stronger, further highlighting the extremely important role of NO in the deep penetration of drugs into tumor tissues.
[0084] It will be easily understood by those skilled in the art that the above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A permeation-enhanced MOF drug-loaded nanoformulation, characterized in that: It includes a MOF carrier, a drug and a modifier; the drug is coated in the porous structure of the MOF carrier, and the drug is a small molecule chemotherapeutic drug and a gas donor drug; the modifier is modified on the surface of the MOF carrier, and the modifier is a hydrophilic ligand, a hydrophilic protein or a hydrophilic polypeptide that can specifically interact with receptors overexpressed in tumor cells; The gas donor drug is used to release gas in situ at the tumor site, thereby causing vascular smooth muscle relaxation and increased blood flow, so as to promote the accumulation and penetration of the small molecule chemotherapeutic drug at the tumor site.
2. The permeation-enhanced MOF drug-loaded nanoformulation according to claim 1, characterized in that: The small molecule chemotherapeutic drug is one or more of curcumin, catechins, gallic acid, paclitaxel, thymoquinone, tamoxifen, vinorelbine, gefitinib, afatinib, osimertinib, crizotinib, topotecan, irinotecan, docetaxel, isabitone, capecitabine, tamoxifen, trastuzumab, lapatinib, doxorubicin hydrochloride and doxorubicin; preferably curcumin.
3. The penetration-enhanced MOF drug-loaded nanoformulation according to claim 1, characterized in that: The gas donor drug is an NO donor drug, an H2S donor drug or a CO donor drug.
4. The permeation-enhanced MOF drug-loaded nanoformulation according to claim 3, characterized in that: The NO donor drug is a nitrate drug, sodium nitroprusside, L-arginine or a nitroso complex; the H2S donor drug is sodium hydrosulfide, sodium sulfide, anethole, aspirin, naproxen, ibuprofen or diclofenac; the CO donor drug is tricarbonyl chloride (glycine) ruthenium, dimanganese decacarbonyl, oxalic acid, boron carboxylate, silicon carboxylate or xanthene carboxylate; Preferably, the nitrate drug is nitroglycerin, and the nitroso compound is S-nitrosoglutathione.
5. The penetration-enhanced MOF drug-loaded nanoformulation according to claim 1, characterized in that: The modification method is covalent bonding or electrostatic adsorption; Preferably, the hydrophilic ligand is hyaluronic acid, folic acid or ubiquitin ligase.
6. The permeation-enhanced MOF drug-loaded nanoformulation according to claim 1, characterized in that: The MOF carrier is a zeolite imidazole framework, a Lavoisier framework material or a porous coordination network.
7. The method for preparing the permeation-enhanced MOF drug-loaded nanoformulation according to any one of claims 1 to 6, characterized in that: The following steps are involved: (1) adding a small molecule chemotherapeutic drug and a gas donor drug to the MOF carrier and mixing them thoroughly so that the small molecule chemotherapeutic drug and the gas donor drug are encapsulated in the porous structure of the MOF carrier to obtain a solution of MOF drug-loaded nanoparticles; (2) adding a modifier to the solution obtained in step (1), wherein the modifier is a hydrophilic ligand, hydrophilic protein or hydrophilic polypeptide that can specifically interact with receptors overexpressed in tumor cells, and the modifier is connected to the surface of the MOF carrier, washed and resuspended to obtain a modifier-modified MOF drug-loaded nanoformulation, i.e., the permeability-enhanced MOF drug-loaded nanoformulation.
8. Use of the permeability-enhanced MOF drug-loaded nanoformulation according to any one of claims 1 to 6 in the preparation of tumor therapeutic drugs.
9. The use according to claim 8, characterized in that The application is specifically as follows: under the conditions of the tumor microenvironment, the permeability-enhanced MOF drug-loaded nanoformulation is used to degrade and release small molecule chemotherapeutic drugs and gas donor drugs, and the gas donor drugs are used to release gas in situ at the tumor site, thereby causing vascular smooth muscle relaxation and increased blood flow, so as to promote the accumulation and penetration of the small molecule chemotherapeutic drugs at the tumor site.
Citation Information
Cited By
Transdermal absorption penetration enhancer as well as preparation method and application thereof in cosmetics
CN121015512A
